Table 3.
Overall Temporal trend in DR screening by gender and MBS item per 100,000 people with diabetes
| MBS no. 12,326 | MBS no. 12,325 | Total | IRR (95% CI) | p-value | ||||
|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Male | Female | |||
| 2016 to 2017 | 20 | 20 | 20 | 31 | 40 | 51 | Ref* | |
| 2017 to 2018 | 57 | 49 | 67 | 99 | 124 | 148 | 0.95 (0.80–1.15) | 0.620 |
| 2018 to 2019 | 76 | 66 | 93 | 143 | 169 | 209 | 0.99 (0.83–1.18) | 0.910 |
| 2019 to 2020 | 132 | 134 | 78 | 104 | 210 | 238 | 0.91 (0.77–1.09) | 0.310 |
| 2020 to 2021 | 93 | 88 | 86 | 113 | 179 | 201 | 0.91 (0.76–1.08) | 0.267 |
| 2021 to 2022 | 75 | 68 | 52 | 60 | 127 | 128 | 0.81 (0.67–0.97) | 0.025 |
| 2022 to 2023 | 105 | 73 | 47 | 62 | 152 | 135 | 0.71 (0.59–0.85) | < 0.001 |
| 2023 to 2024 | 44 | 41 | 62 | 81 | 106 | 122 | 0.93 (0.77–1.12) | 0.442 |
*For interaction term, uptake of males in the year 2016–2017 was taken as reference